The world's worst honey bee parasite is genetically mutating, making it resistant to common treatments used to save hives.

Patients with chronic spontaneous urticaria had positive outcomes weeks after barzolvolimab, according to data presented at ...

Clinical data show remibrutinib treatment leads to significant reductions in urticaria activity scores compared with placebo within the first week.

NVS wins CHMP backing for remibrutinib in chronic spontaneous urticaria, bringing its oral BTK inhibitor closer to EU ...

Improvements in urticaria control and quality of life among patients with chronic inducible urticaria were observed with 20 ...

Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms ...

Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients ...

Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive ...